School Inner-City Asthma Intervention Study (SICAS-2) (SICAS-2)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02291302 |
Recruitment Status :
Completed
First Posted : November 14, 2014
Results First Posted : September 23, 2020
Last Update Posted : August 13, 2021
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Asthma | Other: integrated pest management Other: air purifier Other: No intervention (control) | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 236 participants |
Allocation: | Randomized |
Intervention Model: | Factorial Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | School Inner-City Asthma Intervention Study |
Actual Study Start Date : | January 2015 |
Actual Primary Completion Date : | June 2020 |
Actual Study Completion Date : | June 2020 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Environmental Intervention
Active Classroom air purifiers and school integrated pest management environmental intervention
|
Other: integrated pest management
integrated pest management and environmental strategy Other: air purifier air purifiers |
Placebo Comparator: Sham and Control (control)
Sham air purifiers and no school integrated pest management environmental intervention
|
Other: No intervention (control)
no integrated pest management and sham air purifier |
Placebo Comparator: Active Air Purifier and Control
Active air purifiers and no school integrated pest management environmental intervention
|
Other: air purifier
air purifiers |
Sham Comparator: Sham and Inegrated Pest
Sham air purifiers and active school integrated pest management
|
Other: integrated pest management
integrated pest management and environmental strategy |
- Maximum Number of Days With Asthma Symptoms Within 2 Weeks [ Time Frame: up to 12 months ]
Maximum number of
- Days with wheezing, tightness in the chest, or cough and/or
- Nights with disturbed sleep as a result of asthma and/or
- Days on which the child had to slow down or discontinue play activities because of asthma This is defined as a cumulative assessment from the different variables listed in the Measure Description
- Lung Function [ Time Frame: 12 months ]Spirometry measure of forced expiration volume in 1 second
- School Absences [ Time Frame: 12 months ]Number of school days missed because of asthma/ 2 weeks
- Composite Asthma Severity Index [ Time Frame: 12 months ][a comprehensive severity scale of day symptoms and albuterol use, night symptoms and albuterol use, controller treatment, lung function measures, and exacerbations], health care utilization, and pulmonary function testing (PFT's) including FEV1; FEV1/FVC, FEF25-75. CASI ranges from 0 (lowest) -20 points (highest) with a minimal clinically important difference of 0.49 points. The higher score is worse outcome.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 4 Years to 15 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- grades K-8 with asthma attending sampling/intervention schools
Exclusion Criteria:
- moving schools

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02291302
United States, Massachusetts | |
Boston Children's Hospital | |
Boston, Massachusetts, United States, 02115 |
Principal Investigator: | Wanda Phipatanakul, MD, MS | Boston Children's Hospital |
Documents provided by Wanda Phipatanakul, Boston Children's Hospital:
Responsible Party: | Wanda Phipatanakul, Professor of Pediatrics, Boston Children's Hospital |
ClinicalTrials.gov Identifier: | NCT02291302 |
Other Study ID Numbers: |
U01AI110397 ( U.S. NIH Grant/Contract ) U01AI110397 ( U.S. NIH Grant/Contract ) |
First Posted: | November 14, 2014 Key Record Dates |
Results First Posted: | September 23, 2020 |
Last Update Posted: | August 13, 2021 |
Last Verified: | July 2021 |
Asthma Bronchial Diseases Respiratory Tract Diseases Lung Diseases, Obstructive Lung Diseases |
Respiratory Hypersensitivity Hypersensitivity, Immediate Hypersensitivity Immune System Diseases |